I 
116TH CONGRESS 
2D SESSION 
H. R. 6238 
To amend the Internal Revenue Code of 1986 to restore the amount of 
the orphan drug tax credit, and for other purposes. 
IN THE HOUSE OF REPRESENTATIVES 
MARCH 12, 2020 
Mr. GOTTHEIMER (for himself and Mr. UPTON) introduced the following bill; 
which was referred to the Committee on Ways and Means, and in addi-
tion to the Committee on Energy and Commerce, for a period to be sub-
sequently determined by the Speaker, in each case for consideration of 
such provisions as fall within the jurisdiction of the committee concerned 
A BILL 
To amend the Internal Revenue Code of 1986 to restore 
the amount of the orphan drug tax credit, and for other 
purposes. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as ‘‘Cameron’s Law’’. 
VerDate Sep 11 2014 
04:06 Mar 26, 2020
Jkt 099200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H6238.IH
H6238
pamtmann on DSKBC07HB2PROD with BILLS
SEC. 2. RESTORATION OF AMOUNT OF ORPHAN DRUG TAX 
CREDIT. 
(a) IN GENERAL.—Section 45C(a) of the Internal 
Revenue Code of 1986 is amended by striking ‘‘25 per-
cent’’ and inserting ‘‘50 percent’’. 
(b) EFFECTIVE DATE.—The amendment made by 
this section shall apply to taxable years beginning after 
the date of the enactment of this Act. 
SEC. 3. CDC STUDY ON SURVEILLANCE INFRASTRUCTURE 
FOR RARE DISEASES AND CONDITIONS. 
(a) STUDY.—Not later than 1 year after the date of 
enactment of this Act, the Director of the Centers for Dis-
ease Control and Prevention (in this section referred to 
as the ‘‘Director’’) shall complete a study on enhancing 
and expanding the infrastructure to track the epidemi-
ology of rare diseases and conditions, including with re-
spect to the following: 
(1) Rates of mortality. 
(2) Potential for research and treatment. 
(3) Demographics. 
(4) Diagnosis and progression markers. 
(5) The history of the disease or condition. 
(6) Detection management. 
(b) CONSULTATION.—In conducting the study re-
quired by subsection (a), the Director shall consult with 
relevant experts, including— 
VerDate Sep 11 2014 
04:06 Mar 26, 2020
Jkt 099200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H6238.IH
H6238
pamtmann on DSKBC07HB2PROD with BILLS
(1) epidemiologists with experience in disease 
surveillance; 
(2) representatives of national voluntary health 
associations; 
(3) health information technology experts or 
other information management specialists; 
(4) clinicians with expertise in rare diseases or 
conditions; 
(5) research scientists with expertise in rare 
diseases or conditions, or experience conducting 
translational research or utilizing surveillance sys-
tems for scientific research purposes; and 
(6) patients, and caregivers of patients, with 
rare diseases or conditions. 
(c) REPORT.—Not later than 3 months after com-
pleting the study required by subsection (a), the Director 
shall submit a report to the Congress on the results of 
the study. 
(d) DEFINITION.—In this section, the terms ‘‘rare 
diseases and conditions’’ and ‘‘rare diseases or conditions’’ 
refer to human diseases and conditions that are— 
(1) a rare disease or condition, as defined in 
section 526 of the Federal Food, Drug, and Cos-
metic Act (21 U.S.C. 360bb); or 
VerDate Sep 11 2014 
04:06 Mar 26, 2020
Jkt 099200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H6238.IH
H6238
pamtmann on DSKBC07HB2PROD with BILLS
(2) determined by the Director to be rare and 
lacking in treatment options, so as to warrant con-
sideration in the study required by subsection (a). 
Æ 
VerDate Sep 11 2014 
04:06 Mar 26, 2020
Jkt 099200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6301
E:\BILLS\H6238.IH
H6238
pamtmann on DSKBC07HB2PROD with BILLS